Joseph Rimando

5PUBLICATIONS

25CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Transplantation immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|May 20, 2026

Absolute Risk Trade-offs of Donor Age, Sex, and Graft Source in PTCy-Based Transplantation.

|Feb 04, 2026

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Muhammad Umair Mushtaq, John F DiPersio, Jacques Azzi

|Oct 23, 2025

Remission of <i>TP53</i>-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).

Guenther Koehne, Muhammad U Mushtaq, Lori S Muffly

|Apr 11, 2022

How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond.

Joseph Rimando, Shannon R McCurdy, Leo Luznik

|Dec 20, 2018

HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Joseph Rimando, Michael Slade, John F DiPersio

Pageof 1

Frequent Collaborators

Lori S Muffly

Joseph Maakaron

Jennifer S Whangbo

Nirali N Shah

Michelle I Lin

Melissa M Lee-Sundlov

Giacomo Canesin

Rizwan Romee

Muhammad U Mushtaq

Vanessa Kennedy

Frequent Collaborators

Lori S Muffly

Joseph Maakaron

Jennifer S Whangbo

Nirali N Shah